GlassScriptPhysician profile
Andrew D Burrell
NPI 1558355990
$6,300.27
in general payments reported to CMS, 2019-2025
56 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $718 · 2021: $1,295 · 2022: $1,041 · 2023: $733 · 2024: $596 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.83 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $822.32 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.81 | 2019-2025 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $368.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $261.90 | 2019-2023 | |
| Amgen INC. | $249.36 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $241.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $217.45 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $216.68 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $196.66 | 2020-2025 | Seglentis, Livalo, Zoryve |
| Allergan, INC. | $166.22 | 2019-2020 | |
| Abbott Laboratories | $133.54 | 2019-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $124.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.45 | 2021-2024 | |
| Boston Scientific Corporation | $115.26 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.